NCT07074418View on ClinicalTrials.gov

Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Chronic Kidney Diseases

Interventions

DRUG

Empagliflozin 10 MG then Placebo

Taking Empagliflozin first

DRUG

Placebo then Empagliflozin 10 MG

Taking the Empagliflozin in second

Trial Locations (1)

06000

CHU Nice - Hôpital Pasteur 2, Nice

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Centre Hospitalier Universitaire de Nice

OTHER